Ractigen Therapeutics
中美瑞康
Ractigen Therapeutics
Biotech/Healthcare
Sino-US Ryan Bio (Zhongmei Ruikang) has completed a RMB 200 million Series C financing round, which will be used to advance clinical development of its small nucleic acid innovative drug pipeline and upgrade its technology platform, further consolidating its industry advantage.
Latest round: Series C (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-07-29
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.